Last updated: May 20, 2026
What clinical trials have been published for cyproheptadine hydrochloride?
Cyproheptadine hydrochloride is an established antihistamine (first-generation H1 blocker with antiserotonergic activity) with long-standing OTC and prescription use in multiple indications, including allergic symptoms and appetite stimulation (off-label in many jurisdictions). Public trial activity for cyproheptadine specifically is limited in volume compared with newer drugs, and much of the available evidence is older.
Featured snippet answer. Publicly available cyproheptadine hydrochloride clinical trial reporting is sparse relative to modern therapeutics, with most high-quality clinical evidence dating to earlier decades and fewer recent, drug-specific phase development programs being visible in contemporary registries and publications.
Which cyproheptadine trial types show up most often?
-
Symptomatic allergic or histamine-mediated conditions
Studies typically evaluate antihistaminic efficacy or tolerability, often against placebo or comparator agents, usually in small-to-moderate samples.
-
Pediatric appetite or weight-gain contexts
Many cyproheptadine studies are small and were designed to evaluate appetite stimulation and weight gain, often in pediatric populations and often framed as supportive care.
-
Formulation and bioavailability work rather than new clinical endpoints
For an off-patent, widely marketed active ingredient, contemporary work frequently shifts toward formulation performance, dissolution, and generic equivalence rather than novel clinical efficacy programs.
Recent phase development signal
No clear, globally consolidated signal of new cyproheptadine hydrochloride phase 3 registrational programs is visible from mainstream, late-stage drug development patterns. Market participants generally treat cyproheptadine as a “mature molecule,” with incremental activity driven by product lifecycle management and regulatory maintenance of existing generics rather than new mechanism-of-action repositioning into late phases.
How big is the cyproheptadine hydrochloride market today, and what drives demand?
Cyproheptadine hydrochloride demand is mainly driven by:
- Allergy seasonality (OTC and pharmacy channel movement)
- Pediatric use patterns (where age-appropriate dosing supports continued use)
- Off-label appetite stimulation and weight-gain use in specific clinical settings
- Formulary presence for generic antihistamines
- Availability and price competitiveness in generic segments
Featured snippet answer. Cyproheptadine’s commercial profile is typical of mature antihistamines: demand persists, but growth is constrained by generic competition and low unit margins, with volume tied to seasonal and pediatric practice patterns.
Market structure
- Generic-heavy supply chain: multiple manufacturers supply tablets and syrups; competition is primarily price and distribution-led.
- OTC/institutional mix: OTC use supports stability, while institutional use in allergic symptom management can be sensitive to formulary rules.
- Product forms: tablets and oral liquids dominate. Liquid products can have slightly different demand patterns due to pediatric prescribing.
Pricing and margin dynamics
- High supply elasticity: because cyproheptadine is widely generic, shortages are uncommon.
- Margin compression: price competition typically keeps net realized prices low.
- Packaging and concentration: specific strengths and presentation formats affect local pricing.
When does cyproheptadine hydrochloride lose exclusivity, and are there Orange Book-style blocks?
Cyproheptadine hydrochloride is a mature active ingredient with historical origin coverage. In practical market terms, exclusivity barriers are generally limited to:
- Patent estates on specific formulations, salts/polymorphs, or dosing regimens (if any remain for particular products)
- Device or administration method claims for particular branded presentations
- Application-specific exclusivities tied to individual products rather than the molecule
Featured snippet answer. For the active ingredient cyproheptadine hydrochloride, market exclusivity is not typically a meaningful constraint on generic entry; the controlling factor is whether any still-in-force, product-specific patent claims cover a specific formulation or method of use.
What does that mean for generic entry risk?
- Low molecule-level risk: generic entry is generally not blocked by broad molecule patents for cyproheptadine itself.
- Product-level risk: a subset of later-filed patents, if present on a specific branded formulation, could delay a narrow generic if claims are enforceable and the generic would infringe.
What patents protect cyproheptadine hydrochloride, and how strong is the patent estate?
For established small molecules, patent estates are usually concentrated in:
- Old composition-of-matter or early formulation patents (expired)
- Later-life formulation improvements (some may exist but are often sporadic)
- Method-of-use claims that are tied to specific therapeutic claims
Featured snippet answer. The cyproheptadine hydrochloride patent landscape is expected to be dominated by expired foundational patents, with any remaining enforceable rights likely concentrated in narrow, product-specific formulation or use patents.
How to think about “strength” in mature antihistamines
- Exclusivity at molecule level is typically exhausted
- Remaining value lies in:
- specific oral solution formulations
- specific dosing regimens tied to labeled or off-label use claims (where still patented)
- process improvements that might create manufacturing/IP barriers
What generic entry risks exist for cyproheptadine hydrochloride tablets and syrups?
Generic entry risk is usually low at the API level but non-zero at the product level.
Entry blockers that matter in practice
- Unexpired formulation patents covering specific excipients or dissolution characteristics
- Unexpired method-of-use claims tied to a labeled indication in a niche formulation
- Regulatory holding actions tied to specific application histories (less common now given the molecule age)
Settlement and Paragraph IV dynamics
For mature, widely generic molecules, Paragraph IV filings typically occur when a still-marketed branded product has active Orange Book-listed patents. Cyproheptadine’s widespread generic status reduces the incidence of new Paragraph IV disputes compared with newer branded products.
How do cyproheptadine hydrochloride market projections compare with other first-generation antihistamines?
Cyproheptadine competes with:
- other first-generation oral antihistamines
- second-generation antihistamines (which often take share where tolerated and where sedation is a downside)
- combination allergy products
Featured snippet answer. Projected growth for cyproheptadine typically tracks the lower-growth mature oral antihistamine category, with headwinds from sedating profiles compared with many second-generation alternatives and tailwinds from pediatric/off-label appetite-use persistence in some markets.
Key competitive parameters
- Sedation profile: first-generation differentiation can drive both loyalty (off-label use) and substitution away from use cases where sedation is undesirable.
- Form availability: liquid availability supports pediatric prescribing.
- Therapeutic positioning: where clinicians use cyproheptadine as supportive care for appetite/weight concerns, it can retain volume.
What regulatory status does cyproheptadine hydrochloride have in major markets?
Cyproheptadine is approved and marketed across multiple geographies in generic or branded forms depending on local history. Regulatory focus is typically on:
- maintaining generic approvals under national frameworks
- quality and manufacturing compliance
- bioequivalence and stability for generics and reformulated generics
Featured snippet answer. Regulatory status is mature and distributed. Entry barriers are typically administrative and quality-based rather than patent-based for the active ingredient.
What manufacturing and IP barriers exist for cyproheptadine hydrochloride?
The main barriers in this segment are usually operational rather than legal:
- consistent API sourcing and control strategy
- formulation reproducibility (especially for liquids: viscosity, stability, preservative systems, and taste-masking)
- process validation and batch release testing
IP barriers typically show up only if:
- a still-in-force formulation patent covers a specific oral solution composition or process
- a still-in-force method-of-use claim would be implicated by labeling or promotion
Cyproheptadine hydrochloride clinical evidence gaps: what do they imply for commercialization?
Because cyproheptadine is mature, commercialization depends more on product lifecycle, payer/formulary behavior, and channel distribution than on new clinical evidence generation.
Featured snippet answer. The lack of a visible late-stage development pipeline implies that near-term differentiation comes from formulation, package/strength availability, and distribution economics, not from new clinical outcomes.
Key Takeaways
- Cyproheptadine hydrochloride is a mature, generic-dominant antihistamine with limited modern drug-development visibility; published clinical trial activity is mostly older and supportive.
- Market growth is likely modest, shaped by allergy seasonality, pediatric and supportive care prescribing, and price competition typical of mature oral antihistamines.
- Exclusivity barriers are generally not expected to be molecule-driven; any remaining blocks are most likely product-specific formulation or method-of-use claims.
- Generic and competitive risk is operational (quality, stability, supply chain) more than legal, unless a still-in-force product-specific patent estate applies.
FAQs
- Is cyproheptadine hydrochloride still used for appetite stimulation, and how does that affect demand?
- Which formulation (tablet vs oral syrup) typically drives cyproheptadine unit volume in pediatric markets?
- Do any cyproheptadine hydrochloride product patents commonly delay generic launches in the US?
- How does cyproheptadine’s sedation profile influence substitution vs second-generation antihistamines?
- What stability and preservative constraints dominate cyproheptadine hydrochloride oral liquid reformulation efforts?
References (APA)
- FDA. (n.d.). Drug approvals and related information (public databases). U.S. Food and Drug Administration.
- DailyMed. (n.d.). Cyproheptadine hydrochloride prescribing information and labels. U.S. National Library of Medicine.
- ClinicalTrials.gov. (n.d.). Cyproheptadine hydrochloride clinical studies search results. U.S. National Institutes of Health.
- EMA. (n.d.). European public assessment information for cyproheptadine hydrochloride-containing products. European Medicines Agency.
